Scarica l'app Stockscreener
11.72
3.06%
-0.38
Precedente Chiudi:
$12.10
Aprire:
$12.16
Volume 24 ore:
651.44K
Relative Volume:
0.40
Capitalizzazione di mercato:
$1.32B
Reddito:
-
Utile/perdita netta:
$-44.84M
Rapporto P/E:
-24.94
EPS:
-0.47
Flusso di cassa netto:
$-44.23M
1 W Prestazione:
-13.05%
1M Prestazione:
-21.75%
6M Prestazione:
-16.27%
1 anno Prestazione:
+32.09%
Intervallo 1D:
$11.65
$12.35
Intervallo di 1 settimana:
$11.65
$14.00
Portata 52W:
$7.55
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Confronta SPRY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
11.71 | 1.32B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.76 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.44 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
546.50 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.12 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.39 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-10 | Iniziato | Oppenheimer | Outperform |
| 2024-08-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Reiterato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | Raymond James | Outperform |
| 2024-03-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2025 Earnings Call Transcript - Insider Monkey
What You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade Today - Yahoo Finance
ARS Pharmaceuticals Reports Strong Q1 2025 Performance - TipRanks
SPRY Reports Q1 Revenue Surpassing Expectations, Preps for Key M - GuruFocus
ARS Pharmaceuticals (SPRY) Reports Strong Start with Neffy Launc - GuruFocus
ARS Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: ARS Pharmaceuticals Q1 2025 revenue beats forecast - Investing.com
ARS Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Estimates at $8.0M, EPS Misses at -$0.35 - GuruFocus
Transcript : ARS Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million - marketscreener.com
ARS Pharmaceuticals' Q1 Net Loss Widens, Revenue Tops Estimates - marketscreener.com
ARS Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
ARS Pharmaceuticals Reports First Quarter 2025 Financial - GlobeNewswire
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray) - Yahoo Finance
ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus
Needle-Free Emergency Epinephrine Now Available for Pediatric Patients - medicalbag.com
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
ARS Pharma’s epinephrine nasal spray 1mg now available in US - Yahoo Finance
Neffy Maker Steps Up Awareness for MDs; Launches Kids’ Device - Allergic Living
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to - GlobeNewswire
ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx Website - marketscreener.com
ARS Pharmaceuticals And 2 Other Growth Leaders With Insider Ownership - simplywall.st
(SPRY) Investment Analysis - news.stocktradersdaily.com
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results - The Manila Times
ARS Pharmaceuticals Sets Q1 2025 Earnings Date: Key Updates Expected on Anaphylaxis Treatment Progress - Stock Titan
ALK Abello inks neffy co-promotion deal in USA - The Pharma Letter
ARS Pharmaceuticals Partners with ALK for Neffy Promotion By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals Partners with ALK for Neffy Promotion - Investing.com Australia
ARS Pharmaceuticals Signs Co-Promotion Deal With ALK-Abello for Neffy Nasal Spray in US - marketscreener.com
ARS Pharma in pact with ALK-Abelló for neffy (SPRY:NASDAQ) - Seeking Alpha
ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner And Global Allergy Leader Alk-Abello A/S - marketscreener.com
ALK-Abello (AKBLF) Partners with ARS Pharma for Needle-Free Alle - GuruFocus
ALK enters into neffy® co-promotion agreement in the USA - The Manila Times
ARS Pharmaceuticals and ALK-Abelló A/S Expand Co-Promotion Agreement for neffy® Nasal Spray Ahead of Back-to-School Season - Nasdaq
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians - GlobeNewswire
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ... - Eagle-Tribune
ARS Pharma Partners With ALK to Expand neffy Nasal Spray to 9,000 US Pediatricians | SPRY Stock News - Stock Titan
REG-ALK enters into neffy® co-promotion agreement in the USA - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
ARS Pharmaceuticals Has A Blockbuster Candidate (NASDAQ:SPRY) - Seeking Alpha
(SPRY) On The My Stocks Page - news.stocktradersdaily.com
ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock By Investing.com - Investing.com India
ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock - Investing.com Australia
US High Growth Tech Stocks To Watch Now - Yahoo Finance
ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money - Insider Monkey
How the (SPRY) price action is used to our Advantage - news.stocktradersdaily.com
10 Unstoppable Stocks That Could Double Your Money - Insider Monkey
High Insider Ownership Growth Stocks To Know In April 2025 - simplywall.st
Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28% - simplywall.st
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):